About Us

HAHN-JUN LEE M.Sc., Ph.D.

Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who founded or co-founded Polaryx, Epygenix Therapeutics and Focus Therapeutics, a business catalyst in the biotech-pharma industry. He also co-founded Curyx Partners, LLC, a drug development platform. Hahn-Jun has extensive experience in R&D, deal making, business development, and has consulted with several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He also consulted with several Korean biotechs, venture capital firms, and research institutes.

Hahn-Jun was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the City of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan. He obtained a B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.

ANTHONY LAM CFA, CPA

Anthony Lam, CPA, CFA, is Chief Financial Officer of Polaryx Therapeutics. Prior to joining Polaryx, Anthony served as Chief Investment Officer of Transpac Capital Limited where his responsibilities include defining investment strategy and market positioning, leading recruitment efforts to build investment team, and leading fund-raising efforts on USD and RMB PE funds. Anthony was also former Managing Director and Head of China for Asia Climate Partners (“ACP”) managing a US$450 million fund. Prior to ACP, Anthony was a Managing Director and Co-Head of Asia Pacific for The Rohatyn Group where he served on global investment and management committee with responsibility for the investment management process including advising, research and execution in an asset management capacity. He was also a partner at Citigroup Venture Capital International.

Anthony received a BA (Hons) in Computing Studies from The Hong Kong Polytechnic University and MBA from The Chinese University of Hong Kong.

ANDREW O

Andrew O has over twenty years of experience as an asset management and finance professional. Prior to serving as Polaryx’s Chief Investment Officer, Andrew held multiple positions within traditional fund management as well fundamentally-driven hedge fund investing roles at institutions such as Manulife Investment Management, Horizon Asset International and FrontPoint Partners (Morgan Stanley). Andrew also worked at Goldman Sachs and the International Finance Corporation, the World Bank’s private investment arm.

Andrew graduated from the University of Pennsylvania and undertook Master’s level studies at Yonsei University’s Graduate School of International Studies.

LUIS A ROJAS, M.Sc., Ph.D.

Luis A Rojas M.Sc., Ph.D. is Polaryx’s Chief Clinical Development Officer. Luis is highly experienced Research Scientist Statistician with 30+ years in the pharmaceutical, medical device, CRO, and academia industry. Luis is a Subject-Matter Expert (SME) in Study Design / Adaptive Design for Phase I through Phase IV studies and has amassed more than 20 years of leadership and project management experience, including managing global staff of 140+ Biostatisticians and Statistical Programmers.

Luis was former Head of Study Designs / Adaptive Design unit within Advisory Service Analytics / Center for Statistics in Drug Development in IQVIA, while acting as lead Senior Research Scientist Statistician for the GI, Rare Diseases, Ophthalmology, CNS, Lupus, RA Center of Excellence. Luis received his PhD in Research Statistics from the Rafael Belloso Chacin, Venezuela.

SHRIJAY VIJAYAN, Ph.D.

Shrijay Vijayan, Ph.D. is a technology commercialization and business development executive with a strong network of industry partners and expertise leading an organization’s scientific and technology commercialization efforts, with a bias towards advancing technologies into the marketplace. Prior to joining Polaryx Therapeutics, Jay served as the director of innovation and technology commercialization at the Hospital for Special Surgery in New York and the head of the office of innovation and technology transfer at Rush University Medical Center in Chicago. He is experienced in serving as the primary licensing officer for organization-created discoveries and inventions as well as the safeguard for the organizations’ intellectual property protection.

Jay holds a Master of Business Administration, Entrepreneurship from the University of Illinois in Chicago. He also holds a Doctor of Philosophy in Biology from the City University of New York.

Dr. Kalipada Pahan, Ph.D

Dr. Pahan is a Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center in Chicago. He is also a Veterans Affairs Scientist at the Jesse Brown VA Medical Center. Currently, he is engaged in translational biomedical research involving Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, and Batten Dsease. He is the Editor-in-Chief of the Journal of Multiple Sclerosis, Senior Editor of the Journal of Neuroimmune Pharmacology, Editor of three other journals, and a chartered member of the Clinical Neuroimmunology and Brain Tumors study section at the NIH.

He has over 160 publications and is cited by Wikipedia. He received the outstanding teaching award in 2000, the “Chancellor’s Council Silver U Award” in 2004 and the "Reinhardt Research Scholar Award” in 2005 from the University of Nebraska Medical Center. Recently he also received VA merit awards from the US Department of Veterans Affairs and the Zenith award from the Alzheimer’s Association.

Dr. Raymond Wang, M.D.

Dr. Raymond Wang, M.D. is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s Hospital and a board certified clinical geneticist and biochemical genetics specialist. Dr. Wang is aware of the challenges faced by patients and families with rare diseases such as lysosomal storage disorders. He has committed the program to provide: treatment for the lysosomal disorders that have existing therapies; access to investigational treatment for patients with disorders that currently have no approved / effective therapy, and translational research vital to development of “next generation” treatments and cures for lysosomal storage disorder patients. He has participated in clinical trials for Type 2 Neuronal Ceroid Lipofuscinosis, Pompe Disease, Niemann-Pick C Disease, and Mucopolysaccharidoses. He also is the principal investigator for translational research involving gene therapy and gene editing for treatment of lysosomal storage disorders.

Dr. Wang graduated from Stanford University with Honors and Distinction in Biological Sciences. He earned his medical degree from the University of California, Los Angeles (UCLA), and completed his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center where he served as chief resident in his final year of training. Dr. Wang completed his fellowship in biochemical genetics at the UCLA Intercampus Medical Genetics Program. In 2006, Dr. Wang received the American College of Medical Genetics and Genzyme Fellowship in Biochemical Genetics Award and the Cedars-Sinai Medical Center’s Paul Rubenstein Prize for Excellence in Resident Research. Dr. Wang has been named an Orange County Clinical Biochemical Genetics Physician of Excellence in 2015, 2016, 2017, 2018, and 2019 and nominated for a 2018 Global Genes RARE Champion of Hope Award for his work with children with rare metabolic conditions.

Dr. Angela Schulz, M.D., Ph.D.

Dr. Angela Schulz, M.D., Ph.D. is the director at Children's Hospital, NCL Specialty Clinic International Center of Lysosomal Storage Disorders (ICLD) University Medical Center Hamburg-Eppendorf Hamburg, Germany. Her areas of expertise includes palliative medicine and neuropediatrics.

Dr. Angela was the winner of 2005 Wissenschaftspreis der Gesellschaft für Neuropädiatrie.

Dr. Saadet Andrews, M.D., Ph.D.

Dr. Andrews received training in both clinical metabolic genetics and pediatrics at the Department of Pediatrics, Vienna General Hospital, University of Vienna, Austria. She completed her training on biochemical genetics fellowship and a one-year fellowship in pediatric neurology at the University of British Columbia's Division of Neurology, Department of Pediatrics. Dr. Andrew established the first epilepsy genetics clinic at The Hospital for Sick Children between 2011 to 2020, and began working as a geneticist at the University of Alberta's Department of Medical Genetics in Edmonton. She has also developed the "Epilepsy Genetics Clinic" in the Department to provide genetic diagnostics to the children, teenagers and adults with epilepsy in Northern Alberta.

Dr. Andrew was the winner of the 2015 Epilepsia Clinical Science Prize for her clinical research study "Diagnostic yield of genetic testing in epileptic encephalopathy in childhood".

ALEX YANG J.D., L.L.M.

HAHN-JUN LEE M.Sc., Ph.D.

ANDREW O